Pixelgen Technologies Partners with Karolinska Institutet to Discover Novel Biomarkers for Cancer Immunotherapy Response
核心洞察
Pixelgen Technologies (搜索) has announced a research collaboration with Andreas Lundqvist's Group at Karolinska Institutet to identify novel biomarkers for cancer immunotherapy response using their Proximity Network Assay technology.
The project will analyze the spatial distribution and abundance of more than 150 cell surface proteins in non-small cell lung cancer patients undergoing immune checkpoint inhibitor therapy.
The collaboration aims to advance understanding of single-cell protein interactions in disease and potentially improve patient stratification for immunotherapy treatments.
Pixelgen Technologies (搜索) announced a research collaboration with Andreas Lundqvist's Group at the Department of Oncology-Pathology, Karolinska Institutet, to discover novel biomarkers for cancer immunotherapy response using Pixelgen's Proximity Network Assay (PNA). The project will explore the spatial distribution and abundance of more than 150 cell surface proteins in patients with non-small cell lung cancer who undergo immunotherapy with immune checkpoint inhibitors.
Advanced Spatial Protein Analysis Technology
The collaboration leverages Pixelgen's patented Proximity Network Assay, which delivers nanoscale spatial analysis of immune cell proteins at scale as part of the company's Pixelgen Proxiome Kit. This technology provides researchers with new avenues for drug and biomarker discovery and diagnostics in immunology, immuno-oncology, hematology, and cell therapy.
"Pixelgen's Proximity Network Assay has the potential to bring new insights into the organization and interactions of cell surface proteins, which could aid in the discovery of new biomarkers for immune checkpoint inhibition response and consequently inform treatment regimens for patients," Prof. Andreas Lundqvist said. "While other tools provide protein abundance analysis, Pixelgen's PNA brings a new dimension of understanding to the spatial organization and interactions of cell surface proteins that may prove useful for patient stratification."
Combining Expertise for Immunotherapy Advancement
The collaboration combines the tumor immunology and biology expertise from Prof. Lundqvist's group with Pixelgen's technology and experience in cell surface protein interactomics. Prof. Lundqvist's group has made significant contributions to tumor immunology, particularly in the areas of immune escape and advancing cell-based therapeutic approaches.
"We're very excited to embark on this collaboration with Prof. Lundqvist's group," said Pixelgen Chief Business Development Officer Erik Pettersson. "Our hope is that this research will contribute to the understanding of the role single-cell protein interactions have in disease, identify biomarkers for immunotherapy response, and ultimately lead to the development of improved immunotherapies for cancer patients."
Research Goals and Future Impact
The team aims to submit results from the project to a scientific journal for peer-reviewed publication, and the research will lay the groundwork for future collaborations. The technology's ability to decipher the protein interactomics of single cells in unprecedented ways positions it as a foundational tool for translational research to accelerate advances in immunology, hematology, and cell therapy.
Pixelgen Technologies (搜索) AB, founded in 2020 by a team of experienced innovators and entrepreneurs, is venture-backed and focused on delivering biology at the highest resolution by understanding the molecular basis of cellular function with new tools and technologies.